ThodisE., PassadakisP., VargemezisV., OreopoulosD.G.Peritoneal dialysis: better than, equal to, or worse than hemodialysis? Data worth knowing before choosing a dialysis modality.Perit Dial Int2001; 21(1): 25–35.
2.
FentonS.S., SchaubelD.E., DesmeulesM., MorrisonH.I., MaoY., CoplestonP.Hemodialysis versus peritoneal dialysis: a comparison of adjusted mortality rates.Am J Kidney Dis1997; 30(3): 334–42.
3.
MaiorcaR., CancariniG., ZubaniR., CameriniC., ManiliL., BrunoriG.CAPD viability: a long-term comparison with hemodialysis.Perit Dial Int1996; 16: 276–87.
4.
DaviesS.J., BryanJ., PhillipsL., RussellG.I.Longitudinal changes in peritoneal kinetics: the effects of peritoneal dialysis and peritonitis.Nephrol Dial Transplant1996; 11: 498–506.
TopleyN.Membrane longevity in peritoneal dialysis: impact of infection and bio-incompatible solutions.Adv Ren Replace Ther1998; 5(3): 179–84.
7.
HondaK., NittaK., HoritaS., YumuraW., NiheiH., NagaiR.Accumulation of advanced glycation end products in the peritoneal vasculature of continuous ambulatory peritoneal dialysis patients with low ultra-filtration.Nephrol Dial Transplant1999; 14: 1541–9.
8.
WieslanderA., LindenT., MusiB., CarlssonO., DeppischR.Biological significance of reducing glucose degradation products in peritoneal dialysis fluids.Perit Dial Int2000; 20(Suppl 5): S23–7.
9.
JörresA., BenderT.O., WitowskiJ.Glucose degradation products and the peritoneal mesothelium.Perit Dial Int2000; 20(Suppl 5): S19–22.
10.
HolmesC.J., ShockleyT.R.Strategies to reduce glucose exposure in peritoneal dialysis patients.Perit Dial Int2000; 20(Suppl 2): S37–41.
11.
RippeB., SimonsenO., HeimbürgerO., ChristenssonA., HaraldssonB., StelinG.Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products.Kidney Int2001; 59(1): 348–57.
12.
TranæusA.A long-term study of a bicarbonate/lactate– based peritoneal dialysis solution—clinical benefits. the Bicarbonate/Lactate Study Group.Perit Dial Int2000; 20(5): 516–23.
13.
TopleyN., KaurD., PetersenM.M., JörresA., WilliamsJ.D., FaictD.In vitro effects of bicarbonate and bicarbonate–lactate buffered peritoneal dialysis solutions on mesothelial and neutrophil function.J Am Soc Nephrol1996; 7(2): 218–24.
JonesM.R., MartisL., AlgrimC.E., BernardD., SwartzR., MessanaJ.Amino acid solutions for CAPD— rationale and clinical experience.Miner Electrolyte Metab1992; 18: 309–15.
18.
JonesM., HagenT., BoyleC.A., VoneshE., HamburgerR., CharytanC.Treatment of malnutrition with 1.1% amino acid peritoneal dialysis solution: results of a multicenter outpatient study.Am J Kidney Dis1998; 32(5): 761–9.
19.
GarosiG., GaggiottiE., MonaciG., BrardiS., Di PaoloN.Biocompatibility of a peritoneal dialysis solution with amino acids: histological evaluation in the rabbit.Perit Dial Int1998; 18(6): 610–19.
20.
Garcia–LopezE., LindholmB., TranæusA.Biocompatibility of new peritoneal dialysis solutions: clinical experience.Perit Dial Int2000; 20(Suppl 5): S48–56.
21.
DanielsF.H., LeonardE.F., CortellS.Glucose and glycerol compared as osmotic agents for peritoneal dialysis.Kidney Int1984; 25: 20–5.
22.
MatthysE., DolkartR., LameireN.Extended use of a glycerol dialysate in the treatment of diabetic CAPD patients.Perit Dial Bull1987; 7: 10–15.
23.
NakayamaM., KawaguchiY., KuboH., MiuraY., WatanabeS., SakaiO.Anti-hypertensive effect of low Na concentration (120 mEq/L) solution for CAPD patients.Clin Nephrol1994; 41: 357–63.
24.
HutchisonA.J., GokalR.Improved solutions for peritoneal dialysis: physiological calcium solutions, osmotic agents and buffers.Kidney Int1992; 42(Suppl 38): S153–9.
25.
AlsopR.M.History, chemical, and pharmaceutical development of icodextrin.Perit Dial Int1994; 14(Suppl 2): S5–12.
26.
DaviesD.S.Kinetics of icodextrin.Perit Dial Int1994; 14(Suppl 2): S45–50.
27.
BarreD.E., ChenC., CookerL., MoberlyJ.B.Decreased in vitro formation of AGEs with Extraneal solution compared to dextrose-containing peritoneal dialysis solutions.Adv Perit Dial1999; 15: 12–16.
28.
CookerL.A., ChooC.G., LuneburgP., LamelaJ., HolmesC.J.Effect of icodextrin peritoneal dialysis solution on cell proliferation in vitro.Adv Perit Dial1999; 15: 17–20.
29.
BajoM.A., SelgasR., CastroM.A., del PesoG., DiazC., Sanchez–TomeroJ.A.Icodextrin effluent leads to a greater proliferation than glucose effluent of human mesothelial cells studied ex vivo.Perit Dial Int2000; 20(6): 742–7.
30.
LeeJ.H., ReddyD.K., SaranR., MooreH.L., TwardowskiZ.J., NolphK.D.A.Advanced glycosylation end-products in diabetic rats on peritoneal dialysis using various solutions.Perit Dial Int2000; 20(6): 643–51.
31.
WoodrowG., OldroydB., StablesG., GibsonJ., TurneyJ.H., BrownjohnA.M.Effects of icodextrin in automated peritoneal dialysis on blood pressure and bioelectrical impedance analysis.Nephrol Dial Transplant2000; 15(6): 862–6.
32.
PosthumaN., VerbrughH.A., DonkerA.J., van DorpW., DekkerH.A., PeersE.M.Peritoneal kinetics and mesothelial markers in CCPD using icodextrin for daytime dwell for two years.Perit Dial Int2000; 20(2): 174–80.
33.
WoodrowG., StablesG., OldroydB., GibsonJ., TurneyJ.H., BrownjohnA.M.Comparison of icodextrin and glucose solutions for the daytime dwell in automated peritoneal dialysis.Nephrol Dial Transplant1999; 14(6): 1530–5.
34.
MistryC.D., GokalR.The use of glucose polymer (icodextrin) in peritoneal dialysis: an overview.Perit Dial Int1994; 14(Suppl 3): S158–61.
35.
GokalR., MistryC.D., PeersE., and the MIDAS study group. A United Kingdom multicenter study of icodextrin in continuous ambulatory peritoneal dialysis.Perit Dial Int1994; 14(Suppl 2): S22–7.
36.
GokalR., MistryC.D., PeersE., and the MIDAS study group. Peritonitis occurrence in a multicenter study of icodextrin and glucose in CAPD.Perit Dial Int1995; 15: 226–30.
37.
WilkieM., PlantM., EdwardsL., BrownC.Icodextrin 7.5% dialysate solution (glucose polymer) in patients with ultrafiltration failure: extension of CAPD technique survival.Perit Dial Int1997; 17: 84–6.
38.
DoumaC.E., HiralallJ.K., de WaartD.R., StruijkD.G., KredietR T.Icodextrin with nitroprusside increases ultrafiltration and peritoneal transport during long CAPD dwells.Kidney Int1998; 53: 1014–21.
GokalR.Adequacy, nutrition and outcome in peritoneal dialysis: is there a link?Semin Dial1997; 10: 94–9.
41.
ChurchillD.N., ThorpeK.E., NolphK.D.A., KeshaviahP.R., OreopoulosD.G., PagéD.Increased peritoneal membrane transport is associated with decreased patient and technique survival for continuous peritoneal dialysis patients.J Am Soc Nephrol1998; 9: 1285–92.
42.
WangT., HeimbürgerO., WaniewskiJ., BergströmJ., LindholmB.Increased peritoneal permeability is associated with decreased fluid and small-solute removal and higher mortality in CAPD patients.Nephrol Dial Transplant1998; 13: 1242–9.
43.
DaviesS.J., PhillipsL., RussellG.I.Peritoneal solute transport predicts survival on CAPD independently of residual renal function.Nephrol Dial Transplant1998; 13: 962–8.
44.
DaviesS.J.How to maintain fluid balance in long-term peritoneal dialysis.Perit Dial Int1999; 19(Suppl 2): S332–6.
45.
ColesG.A.Have we underestimated the importance of fluid balance for survival of PD patients?Perit Dial Int1997; 17: 321–6.
46.
WangT., HeimbürgerO., WaniewskiJ., BergströmJ., LindholmB.Time dependence of solute removal during a single exchange.Adv Perit Dial1997; 13: 23–8.
47.
ChungS.H., StenvinkelP., BergströmJ., LindholmB.Biocompatibility of new peritoneal dialysis solutions: what can we hope to achieve?Perit Dial Int2000; 20(Suppl 5): S57–67.
48.
NiebauerJ., VolkH.D., KempM., DominguezM., SchumannR.R., RauchhausM.Endotoxin and immune activation in chronic heart failure: a prospective cohort study.Lancet1999; 353: 1838–42.
49.
FlessnerM.F.. Peritoneal transport physiology: insights from basic research.J Am Soc Nephrol1991; 2: 122–35.
50.
FlessnerM.F.. Net ultrafiltration in peritoneal dialysis: role of direct fluid absorption into peritoneal tissue.Blood Purif1992; 10: 3–4.
51.
WangT., ChenC., HeimbürgerO., WaniewskiJ., BergströmJ., LindholmB.Hyaluronan decreases peritoneal fluid absorption in peritoneal dialysis.J Am Soc Nephrol1997; 8: 1915–20.
52.
WangT., ChengH., HeimbürgerO., WaniewskiJ., BergströmJ., LindholmB.Hyaluronan prevents the decrease in net fluid removal caused by increased dialysate fill volume.Kidney Int1998; 53: 496–502.
53.
WangT., ChengH.H., HeimbürgerO., ChenC., WaniewskiJ., BergströmJ.Hyaluronan decreases peritoneal fluid absorption: effect of molecular weight and concentration of hyaluronan.Kidney Int1999; 55(2): 667–73.
54.
BreborowiczA., PolubinskaA., PawlaczykK., Kuzlan– PawlaczykM., MoberlyJ., MartisL.Intraperitoneal hyaluronan administration in conscious rats: absorption, metabolism, and effects on peritoneal fluid dynamics.Perit Dial Int2001; 21(2): 130–5.
55.
PolubinskaA., PawlaczykK., Kuzlan–PawlaczykM., Wieczorowska–TobisK., ChenC., MoberlyJ.B.Dialysis solution containing hyaluronan: effect on peritoneal permeability and inflammation in rats.Kidney Int2000; 57: 1182–9.
56.
RosengrenB.I., CarlssonO., RippeB.Hyaluronan and peritoneal ultrafiltration: a test of the “filter-cake” hypothesis.Am J Kidney Dis2001; 37: 1277–85.
57.
LaurentC., Johnson–WellsG., HellströmS., Engström– LaurentA., WellsA.F.Localization of hyaluronan in various muscular tissues. A morphological study in the rat.Cell Tissue Res1991; 263: 201–5.
58.
YungS., ColesG.A., WilliamsJ.D., DaviesM.The source and possible significance of hyaluronan in the peritoneal cavity.Kidney Int1994; 46: 527–33.
59.
ComperW.D., LaurentT.C.Physiological function of connective tissue polysaccharides.Physiol Rev1978; 58: 255–315.
60.
LaurentT.C., LaurentU.B.G., FraserJ.R.E.Function of hyaluronan.Ann Rheum Dis1995; 54: 429–32.
ZawiejaD., GarciaC., GrangerH.Oxygen radicals, enzymes, and fluid transport through pericardial interstitium.Am J Physiol1992; 262: H136–43.
63.
Lai–FookS.J., BrownL.V.Effects of electric charge on hydraulic conductivity of pulmonary interstitium.J Appl Physiol1991; 70: 1928–32.
64.
WangT., ChengH.H., HeimbürgerO., ChenC., WaniewskiJ., BergströmJ.Hyaluronan decreases peritoneal fluid absorption: effect of molecular weight and concentration of hyaluronan.Kidney Int1999; 55: 667–73.
65.
GuoQ., WuJ., YeR., LiuS., LindholmB., WangT.Ultra-structural identification of a novel membrane structure on peritoneal surface (Abstract).J Am Soc Nephrol1999; 10: 266A.
66.
MactierR.A., KhannaR., TwardowskiZ.J., MooreH., NolphK.D.A.Influence of phosphatidylcholine on lymphatic absorption during peritoneal dialysis in the rat.Perit Dial Int1988; 8: 179–86.
67.
Di PaoloN., BuoncristianiU., GaggiottiE., CapotondoL., De MiaM.Improvement of impaired ultrafiltration after addition of phosphatidylcholine in patients on CAPD.Perit Dial Bull1986; 6(1): 44–5.
68.
BreborowiczA., WieczorowskaK., WitowskiJ., MartisL., OreopoulosD.G.Phosphatidylcholine and chondroitin sulfate in peritoneal dialysis fluids to preserve membrane function.Perit Dial Int1994; 14(Suppl 3): S139–44.
69.
MaherJ.F.Lubrication of the peritoneum.Perit Dial Int1992; 12(4): 346–9.
70.
DobbieJ.W.Nature and disposition of intracavity and intramembranous phospholipid surface-active material and its role in peritoneal dialysis.Perit Dial Int1998; 18: 151–4.
71.
HillsB.A.Role of surfactant in peritoneal dialysis.Perit Dial Int2000; 20: 503–15.
